Table 2 Clinical profiles of T2DM patients treated with oral hypoglycemic agents (OHAs) in study 2

63.5 (62.4 ± 6.3)

61 (60.8 ± 6.7)

0.025

63 (61.3 ± 6.9)

0.27

62 (60.5 ± 6.7)

0.028

62 (61.1 ± 6.1)

0.50

63 (61.6 ± 6.8)

0.52

183 (80.3)

206 (63.4)

-

152 (74.9)

-

101 (72.1)

-

50 (71.4)

-

216 (70.4)

-

Anti-hypertensive agent and anti-dyslipidemia agent

None

24 (10.5)

49 (15.1)

-

21 (10.3)

-

20 (14.3)

-

11 (15.7)

-

34 (11.1)

-

Both of them

109 (47.8)

141 (43.4)

-

126 (62.1)

-

67 (47.9)

-

30 (42.9)

-

166 (54.1)

-

One of them

95 (41.7)

135 (41.5)

-

56 (27.6)

-

53 (37.9)

-

29 (41.4)

-

107 (34.9)

-

7.3 (7.6 ± 1.5)

6.9 (7.1 ± 1.1)

<0.001

6.6 (6.7 ± 1.0)

<0.001

6.5 (6.8 ± 1.2)

<0.001

6.9 (6.9 ± 0.9)

<0.001

7.3 (7.6 ± 1.3)

0.97

Minimum

4.7

5.4

4.9

5.1

4.8

5.1

Maximum

14.1

14.4

11.4

11.8

9.4

13.7

<6.5%

44 (19.3)

78 (24.0)

87 (42.9)

62 (44.3)

21 (30.0)

29 (9.4)

-

-

-

-

-

6.5 % ≤

184 (80.7)

24.7 (76.0)

116 (57.1)

78 (55.7)

49 (70.0)

278 (90.6)

616 (477 ± 279)

730 (540 ± 261)

0.022

700 (510 ± 263)

0.56

596.5 (499 ± 251)

0.90

524.5 (485 ± 251)

1.00

302 (330 ± 245)

<0.001